(NVO) Novo Nordisk - Ratings and Ratios

Exchange: NYSE • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US6701002056

Insulin, Obesity, Growth, Blood, Hormone

Pharmaceuticals
Market Cap in USD: 254,789m

IPO / Inception: 1982-01-04
12m vs SPY: -39.9%

EPS (Earnings per Share)

EPS CAGR: 96.11%
EPS Trend: 88.0%

Last SUE: 1.50
Qual. Beats: 1

Revenue

Rev. CAGR: 19.59%
Rev. Trend: 96.6%

Last SUE: -0.03
Qual. Beats: 0

Dividends

Dividend Yield	2.67%
Yield on Cost 5y	5.21%
Yield CAGR 5y	2.82%
Payout Consistency	96.2%
Payout Ratio	7.2%

Risk via 5d forecast
Volatility	35.3%
Value at Risk 5%th	52.1%
Relative Tail Risk	-10.23%

Reward TTM
Sharpe Ratio	-0.52
Alpha	-45.24
CAGR/Max DD	-0.05

Character TTM
Hurst Exponent	0.372
Beta	0.852
Beta Downside	0.837

Drawdowns 3y
Max DD	68.50%
Mean DD	23.61%
Median DD	8.73%

Description: NVO Novo Nordisk December 01, 2025

Novo Nordisk A/S (NYSE:NVO) is a Danish-based, globally active pharmaceutical group that develops, manufactures, and markets drugs across two main segments: Diabetes & Obesity Care and Rare Disease. The Diabetes & Obesity segment covers insulin, GLP-1 agonists, and emerging cardiovascular therapies, while the Rare Disease segment focuses on treatments for rare blood and endocrine disorders, plus hormone replacement products. The company also supplies delivery devices such as insulin and growth-hormone pens, and offers digital tools like smart insulin pens and the Dose Check app to improve adherence.

Key metrics that reinforce Novo Nordisk’s market position include 2023 revenue of ≈ DKK 140 billion (~US$ 20 bn) and an R&D spend of ≈ DKK 13 billion, representing roughly 9 % of sales-well above the pharmaceutical industry average. The firm’s GLP-1 portfolio (e.g., Ozempic, Wegovy) has driven double-digit growth, capitalising on the global rise in obesity prevalence (projected to affect > 1 billion adults by 2030). Additionally, Novo Nordisk’s partnership with Valo Health aims to accelerate cardiometabolic drug discovery, reflecting a broader industry shift toward AI-enabled pipeline development.

For a deeper quantitative view, you may find ValueRay’s analyst dashboard useful.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (103.77b TTM) > 0 and > 6% of Revenue (6% = 18.94b TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA -4.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -16.63% (prev -4.88%; Δ -11.75pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.24 (>3.0%) and CFO 123.78b > Net Income 103.77b (YES >=105%, WARN >=100%)

Net Debt (69.13b) to EBITDA (163.70b) ratio: 0.42 <= 3.0 (WARN <= 3.5)

Current Ratio 0.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (4.45b) change vs 12m ago -0.31% (target <= -2.0% for YES)

Gross Margin 82.05% (prev 84.66%; Δ -2.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 69.38% (prev 68.08%; Δ 1.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 8.15 (EBITDA TTM 163.70b / Interest Expense TTM 17.96b) >= 6 (WARN >= 3)

Altman Z'' 3.08

(A) -0.10 = (Total Current Assets 181.88b - Total Current Liabilities 234.36b) / Total Assets 512.29b

(B) 0.33 = Retained Earnings (Balance) 168.53b / Total Assets 512.29b

(D) 0.50 = Book Value of Equity 169.90b / Total Liabilities 342.39b

Total Rating: 3.08 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 89.15

1. Piotroski 6.0pt

2. FCF Yield 3.69%

3. FCF Margin 19.88%

4. Debt/Equity 0.60

5. Debt/Ebitda 0.42

6. ROIC - WACC (= 35.60)%

7. RoE 66.95%

8. Rev. Trend 96.64%

9. EPS Trend 87.97%

What is the price of NVO shares?

As of January 13, 2026, the stock is trading at USD 59.86 with a total of 18,994,912 shares traded.
Over the past week, the price has changed by +8.62%, over one month by +19.29%, over three months by +4.10% and over the past year by -27.31%.

Is NVO a buy, sell or hold?

Novo Nordisk has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold NVO.

Strong Buy: 4
Buy: 1
Hold: 5
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the NVO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	54.7	-8.6%
Analysts Target Price	54.7	-8.6%
ValueRay Target Price	56.7	-5.2%

NVO Fundamental Data Overview January 10, 2026

Market Cap DKK = 1631.87b (254.79b USD * 6.4048 USD.DKK)
P/E Trailing = 15.7096
P/E Forward = 16.0
P/S = 0.8073
P/B = 9.5982
P/EG = 2.4514
Beta = 0.358
Revenue TTM = 315.60b DKK
EBIT TTM = 146.44b DKK
EBITDA TTM = 163.70b DKK
Long Term Debt = 89.18b DKK (from longTermDebt, last quarter)
Short Term Debt = 12.03b DKK (from shortTermDebt, last quarter)
Debt = 101.21b DKK (from shortLongTermDebtTotal, last quarter)
Net Debt = 69.13b DKK (from netDebt column, last quarter)
Enterprise Value = 1700.50b DKK (1631.87b + Debt 101.21b - CCE 32.58b)
Interest Coverage Ratio = 8.15 (Ebit TTM 146.44b / Interest Expense TTM 17.96b)
EV/FCF = 27.11x (Enterprise Value 1700.50b / FCF TTM 62.74b)
FCF Yield = 3.69% (FCF TTM 62.74b / Enterprise Value 1700.50b)
FCF Margin = 19.88% (FCF TTM 62.74b / Revenue TTM 315.60b)
Net Margin = 32.88% (Net Income TTM 103.77b / Revenue TTM 315.60b)
Gross Margin = 82.05% ((Revenue TTM 315.60b - Cost of Revenue TTM 56.66b) / Revenue TTM)
Gross Margin QoQ = 76.12% (prev 83.29%)
Tobins Q-Ratio = 3.32 (Enterprise Value 1700.50b / Total Assets 512.29b)
Interest Expense / Debt = 4.95% (Interest Expense 5.01b / Debt 101.21b)
Taxrate = 21.60% (5.51b / 25.52b)
NOPAT = 114.81b (EBIT 146.44b * (1 - 21.60%))
Current Ratio = 0.78 (Total Current Assets 181.88b / Total Current Liabilities 234.36b)
Debt / Equity = 0.60 (Debt 101.21b / totalStockholderEquity, last quarter 169.90b)
Debt / EBITDA = 0.42 (Net Debt 69.13b / EBITDA 163.70b)
Debt / FCF = 1.10 (Net Debt 69.13b / FCF TTM 62.74b)
Total Stockholder Equity = 155.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 22.81% (Net Income 103.77b / Total Assets 512.29b)
RoE = 66.95% (Net Income TTM 103.77b / Total Stockholder Equity 155.00b)
RoCE = 59.97% (EBIT 146.44b / Capital Employed (Equity 155.00b + L.T.Debt 89.18b))
RoIC = 44.36% (NOPAT 114.81b / Invested Capital 258.80b)
WACC = 8.76% (E(1631.87b)/V(1733.09b) * Re(9.06%) + D(101.21b)/V(1733.09b) * Rd(4.95%) * (1-Tc(0.22)))
Discount Rate = 9.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.34%
[DCF Debug] Terminal Value 76.03% ; FCFF base≈64.61b ; Y1≈67.40b ; Y5≈77.66b
Fair Price DCF = 329.6 (EV 1179.31b - Net Debt 69.13b = Equity 1110.18b / Shares 3.37b; r=8.76% [WACC]; 5y FCF grow 4.61% → 2.90% )
EPS Correlation: 87.97 | EPS CAGR: 96.11% | SUE: 1.50 | # QB: 1
Revenue Correlation: 96.64 | Revenue CAGR: 19.59% | SUE: -0.03 | # QB: 0
EPS next Year (2026-12-31): EPS=22.38 | Chg30d=+0.442 | Revisions Net=-3 | Growth EPS=-2.8% | Growth Revenue=-0.9%

Additional Sources for NVO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle